There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...
The biotech stock's lead therapy is looking at some competition.
Zai Lab's shares benefited from positive clinical trial news.
Find out if AbbVie can overcome sinking sales of its top-selling product.
The company has been a strong value stock but faces big changes this year.
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™...
Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel...
Genmab A/S (Nasdaq: GMAB):
Genmab A/S (Nasdaq: GMAB) today announced the results from multiple clinical trials evaluating epcoritamab (DuoBody ® -CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in...